These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19911440)

  • 41. The added costs of depression to medical care.
    Franco K; Tamburino M; Campbell N; Zrull J; Evans C; Bronson D
    Pharmacoeconomics; 1995 Apr; 7(4):284-91. PubMed ID: 10155318
    [No Abstract]   [Full Text] [Related]  

  • 42. [Cost-effectiveness of a brief intervention to support indigenous women in Hidalgo (Mexico) who live with alcohol abusers].
    Rey GN; Aguilar PS; Pérez FC; Orford J; Escudero GS; Sainz MT
    Rev Panam Salud Publica; 2016 Feb; 39(2):69-75. PubMed ID: 27754523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What does treatment of depression really cost?
    Croghan TW; Obenchain RL; Crown WE
    Health Aff (Millwood); 1998; 17(4):198-208. PubMed ID: 9691563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Obtaining utility estimates of the health value of commonly prescribed treatments for asthma and depression.
    Edelen MO; Burnam MA; Watkins KE; Escarce JJ; Huskamp H; Goldman HH; Rachelefsky G
    Med Decis Making; 2008; 28(5):732-50. PubMed ID: 18725407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reducing the cost and burden of depression: incorporate heart and get an early start.
    Goldstein BI
    J Clin Psychiatry; 2015 Feb; 76(2):e216-7. PubMed ID: 25742210
    [No Abstract]   [Full Text] [Related]  

  • 46. The Role of Strategy in Health Care.
    Sharan AD; Schroeder GD; Millhouse PW; West ME; Vaccaro AR
    J Spinal Disord Tech; 2015 Nov; 28(9):332-4. PubMed ID: 26466340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Opportunities for depression disease management: a pharmacy benefit manager's experience.
    Fulop G; Kelly MA; Robinson D; Brown DR; Carides P; Brookler R; Suppapanya N
    Depress Anxiety; 1999; 10(2):61-7. PubMed ID: 10569128
    [No Abstract]   [Full Text] [Related]  

  • 48. Cost-effectiveness in psychotherapy.
    Wolberg LR
    J Am Acad Psychoanal; 1981 Jan; 9(1):1-5. PubMed ID: 6782047
    [No Abstract]   [Full Text] [Related]  

  • 49. The Value Equation: Enhancing Patient Outcomes While Constraining Costs.
    Scheurer D; Crabtree E; Cawley PJ; Lee TH
    Am J Med Sci; 2016 Jan; 351(1):44-51. PubMed ID: 26802757
    [No Abstract]   [Full Text] [Related]  

  • 50. Adding Cost-effectiveness to Define Low-Value Care.
    Pandya A
    JAMA; 2018 May; 319(19):1977-1978. PubMed ID: 29710341
    [No Abstract]   [Full Text] [Related]  

  • 51. The value of a model to consider the cost-effectiveness of interventions for the treatment of major depressive disorder in Canada.
    Clement F; Kirkham J
    CMAJ; 2023 Nov; 195(44):E1518-E1519. PubMed ID: 37963615
    [No Abstract]   [Full Text] [Related]  

  • 52. A Predictive Modeling Approach to Estimating Seismic Retrofit Costs.
    Fung JF; Sattar S; Butry DT; McCabe SL
    Earthq Spectra; 2020; 36(2):. PubMed ID: 33089251
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment Patterns and Health Care Costs in Patients with Depression Treated with Antidepressant only or Combined with Benzodiazepine: Results From a Japanese Claims Database Analysis.
    Jamotte A; Clay E; Onishi Y; Aballéa S; Toumi M
    Value Health; 2014 Nov; 17(7):A466. PubMed ID: 27201322
    [No Abstract]   [Full Text] [Related]  

  • 54. Internet-delivered cognitive behavioural therapy for insomnia disorder in depressed patients treated at an outpatient clinic for mood disorders: protocol of a randomised controlled trial.
    Schotanus AY; Dozeman E; Ikelaar SLC; van Straten A; Beekman ATF; van Nassau F; Bosmans JE; van Schaik A
    BMC Psychiatry; 2023 Jan; 23(1):75. PubMed ID: 36707843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health Related Quality of Life in Major Depressive Disorder: evolution in time and factors associated.
    Martín-Fernández J; Del Nido-Varo LP; Vázquez-de-la-Torre-Escalera P; Candela-Ramírez R; Ariza-Cardiel G; García-Pérez L; Ramos-García V; Retolaza A; Bilbao A
    Actas Esp Psiquiatr; 2022 Jan; 50(1):15-26. PubMed ID: 35103294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment.
    Johnson SC; Williams DC; Brinton D; Chew M; Simpson A; Andrews AL
    Hosp Pediatr; 2021 Jan; 11(1):88-93. PubMed ID: 33293266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessing value in health care: using an interpretive classification system to understand existing practices based on a systematic review.
    Seixas BV; Dionne F; Conte T; Mitton C
    BMC Health Serv Res; 2019 Aug; 19(1):560. PubMed ID: 31409369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does online insomnia treatment reduce depressive symptoms? A randomized controlled trial in individuals with both insomnia and depressive symptoms.
    van der Zweerde T; van Straten A; Effting M; Kyle SD; Lancee J
    Psychol Med; 2019 Feb; 49(3):501-509. PubMed ID: 29747706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blended vs. face-to-face cognitive behavioural treatment for major depression in specialized mental health care: study protocol of a randomized controlled cost-effectiveness trial.
    Kooistra LC; Wiersma JE; Ruwaard J; van Oppen P; Smit F; Lokkerbol J; Cuijpers P; Riper H
    BMC Psychiatry; 2014 Oct; 14():290. PubMed ID: 25326035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and cost effectiveness of guided online treatment for patients with major depressive disorder on a waiting list for psychotherapy: study protocol of a randomized controlled trial.
    Kenter RM; van Straten A; Hobbel SH; Smit F; Bosmans J; Beekman A; Cuijpers P
    Trials; 2013 Dec; 14():412. PubMed ID: 24289099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.